The reagent shall be compatible with the optimal throughput of the analyzer systems and shall not interfere with the optimum performance of the other immunoassay procedures performed on these instruments.
The Department of Defense (DoD) Drug Demand Reduction Program (DDRP) has a requirement for Benzodiazepine Immunoassay reagent kits.
A vendor’s reagent proposal which requires a separate pre-treatment of each specimen prior to testing on the analyzer will not be considered acceptable. The reagent shall be compatible with the optimal throughput of the analyzer systems and shall not interfere with the optimum performance of the other immunoassay procedures performed on these instruments.
The Medical Readiness Contracting Office – Pacific intends to issue a bulk-funded BPA call to Abbott Laboratories Inc. for Clinical Chemistry and Immunoassay reagents for May 2024 for Tripler Army Medical Center, Hawaii.
Header InformationBid Number: MDBCG31034746 Description: RFB B-1193 Enzyme Immunoassay Reagent Kits and Related Supplies, Term Agreement Bid Opening Date: 09/15/2017 03:00:00 PM Purchaser: Dayle Deemer Organization: Baltimore County Government Department: BCGPURCH - BALTIMORE COUNTY PURCHASING DIVISION Location: PURCH - BALTIMORE COUNTY PURCHASING DIVISION Fiscal Year: 18 Type Code: IT - Invitation to Bid (ITB) Allow Electronic Quote: No Alternate
Combined Synopsis Solicitation IAW FAR Subpart 12.6Chemistry and Immunoassay Reagent Testing Supplies in support of Raymond W. Bliss Army Health Center (RWBAHC), at Fort Huachuca, ArizonaThis is a combined synopsis/solicitation for commercial items prepared in accordance with the format in the Federal Acquisition Regulation (FAR) Subpart 12.6, as supplemented with additional information included in this notice.
The package insert and information for the analyzer settings shall contain the information necessary for the FTDTLs to use the immunoassay kits consistent with the device’s FDA approval.2.2. The immunoassay is limited to a two (2) reagent assay procedure. A respondent’s reagent which requires a separate pre-treatment of each specimen prior to testing on the analyzer will not be considered acceptable. 2.3.
